By Lisa Kerner
Erie, Pa., Feb. 14 - Acologix, Inc. said it has closed a second round of $4.5 million series C financing.
Proceeds from the financing will be primarily used for phase 3 clinical development of AC-820, Acologix' drug candidate for the treatment of uremic pruritus in dialysis patients. Funding will also be used for continued development of the company's hard tissue regeneration compound, AC-100, and AC- 200, aimed at reducing serum phosphate levels associated with chronic kidney disease.
New institutional and venture capital investors joined existing shareholders in the second closing.
In addition to the first closing from December, Acologix has now raised a total of $30 million in series C funds. Acologix has raised about $77 million to date through three rounds of private financing.
Acologix is a privately held biopharmaceutical company that develops and commercializes biopharmaceuticals for osteo-renal diseases. The company is based in Hayward, Calif.
| Issuer: | Acologix, Inc.
|
| Issue: | Series C preferred stock
|
| Amount: | $4.5 million
|
| Announcement date: | Feb. 14
|
|
|
© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere.
For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.
